Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 19 results.
User Information
Export Records
  1. 1.   Intervening in beta-Catenin Signaling by Sulindac Inhibits S100A4-Dependent Colon Cancer Metastasis
  2. Stein, U.; Arlt, F.; Smith, J.; Sack, U.; Herrmann, P.; Walther, W.; Lemm, M.; Fichtner, I.; Shoemaker, R. H.; Schlag, P. M.
  3. Neoplasia. 2011, Feb; 13(2): 131-144.
  1. 2.   Cancer and Inflammation: Promise for Biologic Therapy
  2. Demaria, S.; Pikarsky, E.; Karin, M.; Coussens, L. M.; Chen, Y. C.; El-Omar, E. M.; Trinchieri, G.; Dubinett, S. M.; Mao, J. T.; Szabo, E.; Krieg, A.; Weiner, G. J.; Fox, B. A.; Coukos, G.; Wang, E.; Abraham, R. T.; Carbone, M.; Lotze, M. T.
  3. Journal of Immunotherapy. 2010, May; 33(4): 335-351.
  1. 3.   BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports
  2. Toro, J. R.; Wei, M. H.; Glenn, G. M.; Weinreich, M.; Toure, O.; Vocke, C.; Turner, M.; Choyke, P.; Merino, M. J.; Pinto, P. A.; Steinberg, S. M.; Schmidt, L. S.; Linehan, W. M.
  3. Journal of Medical Genetics. 2008 45(6): 321-331.
  1. 4.   Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells
  2. Lou, J. R.; Fatima, N.; Xiao, Z.; Stauffer, S.; Smythers, G.; Greenwald, P.; Ali, I. U.
  3. Cancer Epidemiology Biomarkers & Prevention. 2006, Sep; 15(9): 1598-1606.
  1. 5.   Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro
  2. Ciolino, H. P.; MacDonald, C. J.; Memon, O. S.; Bass, S. E.; Yeh, G. C.
  3. Carcinogenesis. 2006, Aug; 27(8): 1586-1592.
  1. 6.   Smad4 signalling in T cells is required for suppression of gastrointestinal cancer
  2. Kim, B. G.; Li, C. L.; Qiao, W. H.; Mamura, M.; Kasperczak, B.; Anver, M.; Wolfraim, L.; Hong, S.; Mushinski, E.; Potter, M.; Kim, S. J.; Fu, X. Y.; Deng, C. X.; Letterio, J. J.
  3. Nature. 2006, Jun; 441(7096): 1015-1019.
  1. 7.   Precancer in mice: Animal models used to understand, prevent, and treat human precancers
  2. Cardiff, R. D.; Anver, M. R.; Boivin, G. P.; Bosenberg, M. W.; Maronpot, R. R.; Molinolo, A. A.; Nikitin, A. Y.; Rehg, J. E.; Thomas, G. V.; Russell, R. G.; Ward, J. M.
  3. Toxicologic Pathology. 2006 34(6): 699-707.
  1. 8.   High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors
  2. Vocke, C. D.; Yang, Y. F.; Pavlovich, C. P.; Schmidt, L. S.; Nickerson, M. L.; Torres-Cabala, C. A.; Merino, M. J.; Walther, M. M.; Zbar, B.; Linehan, W. M.
  3. Journal of the National Cancer Institute. 2005, JUN 15; 97(12): 931-935.
  1. 9.   Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome
  2. Schmidt, L. S.; Nickerson, M. L.; Warren, M. B.; Glenn, G. M.; Toro, J. R.; Merino, M. J.; Turner, M. L.; Choyke, P. L.; Sharma, N.; Peterson, J.; Morrison, P.; Maher, E. R.; Walther, M. M.; Zbar, B.; Linehan, W. M.
  3. American Journal of Human Genetics. 2005, JUN; 76(6): 1023-1033.
  1. 10.   Birt-Hogg-Dube syndrome, a genodermatosis that increases risk for renal carcinoma
  2. Schmidt, L. S.
  3. Current Molecular Medicine. 2004, DEC; 4(8): 877-885.
  1. 11.   Serum proteomic profiles suggest celecoxib-modulated targets and response predictors
  2. Zhen, X. A.; Luke, B. T.; Izmirlian, G.; Umar, A.; Lynch, P. M.; Phillips, R. K. S.; Patterson, S.; Conrads, T. P.; Veenstra, T. D.; Greenwald, P.; Hawk, E. T.; Ali, L. U.
  3. Cancer Research. 2004 64(8): 2904-2909.
  1. 12.   Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex
  2. Mei, J. M.; Borchert, G. L.; Donald, S. P.; Phang, J. M.
  3. Carcinogenesis. 2002 23(12): 2119-2122.
  1. 13.   Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome
  2. Zbar, B.; Alvord, W. G.; Glenn, G.; Turner, M.; Pavlovich, C. P.; Schmidt, L.; Walther, M.; Choyke, P.; Weirich, G.; Hewitt, S. M.; Duray, P.; Gabril, F.; Greenberg, C.; Merino, M. J.; Toro, J.; Linehan, W. M.
  3. Cancer Epidemiology Biomarkers & Prevention. 2002 11(4): 393-400.
  1. 14.   Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
  2. Taverna, P.; Liu, L.; Hanson, A. J.; Monks, A.; Gerson, S. L.
  3. Cancer Chemotherapy and Pharmacology. 2000 46(6): 507-516.
  1. 15.   Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells
  2. Mei, J. M.; Hord, N. G.; Winterstein, D. F.; Donald, S. P.; Phang, J. M.
  3. Faseb Journal. 2000 14(9): 1188-1201.
  1. 16.   hMSH5: A human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis
  2. Bocher, T.; Barusevicius, A.; Snowden, T.; Rasio, D.; Guerrette, S.; Robbins, D.; Schmidt, C.; Burczak, J.; Croce, C. M.; Copeland, T.; Kovatich, A. J.; Fishel, R.
  3. Cancer Research. 1999 59(4): 816-822.
  1. 17.   Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity
  2. Ali, I. U.; Schriml, L. M.; Dean, M.
  3. Journal of the National Cancer Institute. 1999 91(22): 1922-1932.
  1. 18.   Differential expression of nitric oxide synthase II and prostaglandin endoperoxide H synthase-2 in conditionally immortal mouse colon epithelial cells contrasting in Apc genotype
  2. Mei, J. M.; Hord, N. G.; Phang, J. M.
  3. Annual Meeting of the American Association for Cancer Research. 1997, 38 A3872.
  1. 19.   Mouse Models of Human Disease .2. Recent Progress and Future Directions
  2. Bedell, M. A.; Largaespada, D. A.; Jenkins, N. A.; Copeland, N. G.
  3. Genes & Development. 1997 11(1): 11-43.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel